StockData
Guardant Health, Inc. logo

Guardant Health, Inc.

GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$145.83+0.24 (+0.16%)

Close on Nov 20, 2026Market cap $19.57BP/E –Yield –

Guardant Health Shield Colorectal Cancer Screening Test Volume by Quarter

Guardant Health Shield Colorectal Cancer Screening Test Volume: 83,000 in Q3 2026, up 245.8% from a year earlier. That is the highest of the 8 quarters on record here.

Latest, Q3 2026
83,000
Period ended Sep 30, 2026
Change on a year earlier
+245.8%
24,000 in Q3 2025
History
8 quarters
Since Q4 2024
Sources
8
Documents cited below

Where the Q3 2026 figure comes from

“Screening revenue of $67.6 million, an increase of 180%, and 83,000 Shield tests, an increase of 246%”

Source: Guardant Health Form 8-K Earnings Release (filed 2026-11-05) ↗

Commercial Shield blood-based colorectal cancer (CRC) screening tests reported following FDA premarket approval and U.S. commercial launch in Q4 2024.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up shield Colorectal Cancer Screening Test Volume

Cite this data

StockData. (2026). Guardant Health Shield Colorectal Cancer Screening Test Volume, quarterly Q4 2024–Q3 2026 [Data set]. Compiled from Guardant Health SEC filings and investor materials. https://stockdatahq.com/stocks/gh/kpis/shield-screening-test-volume

See every metric in the Guardant Health KPI table. Data updated Nov 7, 2026.

See a number that looks wrong?